{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:28:13Z","timestamp":1786609693866,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.7759\/cureus.114454","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:40:12Z","timestamp":1786606812000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Samih Abdelmutalab","family":"Mohamed Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lima","family":"Gharbawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namaa","family":"Elshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eltayeb Osman","family":"Elfaki Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Fathelrahman Mokhtar","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asjed Salaheldin","family":"Hassan Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem Mohamed","family":"Yousif Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hadi  M","family":"Alhajri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024, 403:1027-50. 10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe A","year":"2022","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022, 7:009773. 10.1136\/bmjgh-2022-009773","journal-title":"BMJ Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs A","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023, 330:2000-15. 10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies M","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, et al.. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397:971-84. 10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez PJ","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024, 184:1056-64. 10.1001\/jamainternmed.2024.2525","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-024-07137-0","article-title":"Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study","volume":"34","author":"Jamal M","year":"2024","unstructured":"Jamal M, Alhashemi M, Dsouza C, Al-Hassani S, Qasem W, Almazeedi S, Al-Sabah S. Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study. Obes Surg. 2024, 34:1324-32. 10.1007\/s11695-024-07137-0","journal-title":"Obes Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102777","article-title":"Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study","volume":"75","author":"Anson M","year":"2024","unstructured":"Anson M, Henney AE, Broadwell N, et al.. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. EClinicalMedicine. 2024, 75:102777. 10.1016\/j.eclinm.2024.102777","journal-title":"EClinicalMedicine"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16343","article-title":"Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting","volume":"27","author":"Trinh H","year":"2025","unstructured":"Trinh H, Donovan A, McAdam-Marx C. Real-world effectiveness of tirzepatide versus semaglutide for weight loss in overweight or obese patients in an ambulatory care setting. Diabetes Obes Metab. 2025, 27:3523-5. 10.1111\/dom.16343","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan H","year":"2025","unstructured":"Gasoyan H, Butsch WS, Schulte R, et al.. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity (Silver Spring). 2025, 33:1657-67. 10.1002\/oby.24331","journal-title":"Obesity (Silver Spring)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03340-2","article-title":"Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE)","volume":"42","author":"Ng CD","year":"2025","unstructured":"Ng CD, Divino V, Wang J, Toliver JC, Buss M. Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE). Adv Ther. 2025, 42:5468-80. 10.1007\/s12325-025-03340-2","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.98858","article-title":"Efficacy and safety of tirzepatide and semaglutide for obesity management: a real-world comparison","volume":"17","author":"Shil KK","year":"2025","unstructured":"Shil KK, Hira AD, Bakchi S, Paul SK, Hossain M, Ghosh DK. Efficacy and safety of tirzepatide and semaglutide for obesity management: a real-world comparison. Cureus. 2025, 17:e98858. 10.7759\/cureus.98858","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70172","article-title":"Weight loss in people with type 1 diabetes over 12\u2009months: real-world data comparing tirzepatide, semaglutide and liraglutide","volume":"28","author":"Al Ozairi E","year":"2026","unstructured":"Al Ozairi E, Irshad M, Alkandari J, Sojan L, Alroudhan D, Alotaibi N, le Roux CW. Weight loss in people with type 1 diabetes over 12\u2009months: real-world data comparing tirzepatide, semaglutide and liraglutide. Diabetes Obes Metab. 2026, 28:166-73. 10.1111\/dom.70172","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02792-1","article-title":"Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study","volume":"49","author":"le Roux CW","year":"2026","unstructured":"le Roux CW, Done N, Brnabic AJ, et al.. Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study. J Endocrinol Invest. 2026, 49:413-23. 10.1007\/s40618-025-02792-1","journal-title":"J Endocrinol Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S594898","article-title":"Real-world effectiveness and safety of tirzepatide, semaglutide, and liraglutide in adults with overweight or obesity without diabetes: a comparative study","volume":"19","author":"Cetiner S","year":"2026","unstructured":"Cetiner S. Real-world effectiveness and safety of tirzepatide, semaglutide, and liraglutide in adults with overweight or obesity without diabetes: a comparative study. Diabetes Metab Syndr Obes. 2026, 19:594898. 10.2147\/DMSO.S594898","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86080","article-title":"Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies","volume":"17","author":"Munawar N","year":"2025","unstructured":"Munawar N, Mahato A, Rawat A, et al.. Tirzepatide versus semaglutide for weight loss in overweight and obese adults: a systematic review and meta-analysis of direct comparative studies. Cureus. 2025, 17:e86080. 10.7759\/cureus.86080","journal-title":"Cureus"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04102-x","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice","volume":"32","author":"Kr\u00fcger N","year":"2026","unstructured":"Kr\u00fcger N, Schneeweiss S, Desai RJ, et al.. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice. Nat Med. 2026, 32:342-52. 10.1038\/s41591-025-04102-x","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls SJ","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL, et al.. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025, 393:2409-20. 10.1056\/NEJMoa2505928","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521957-comparative-efficacy-and-safety-of-tirzepatide-versus-semaglutide-for-obesity-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:40:12Z","timestamp":1786606812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521957-comparative-efficacy-and-safety-of-tirzepatide-versus-semaglutide-for-obesity-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.114454","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}